Characterization of Anaphylaxis After ecallantide (cas 460738-38-9) Treatment of Hereditary Angioedema Attacks
-
Add time:07/11/2019 Source:sciencedirect.com
Backgroundecallantide (cas 460738-38-9) is a human plasma kallikrein inhibitor indicated for treatment of acute attacks of hereditary angioedema for patients 12 years of age and older. Ecallantide is produced in Pichia pastoris yeast cells by recombinant DNA technology. Use of ecallantide has been associated with a risk of hypersensitivity reactions, including anaphylaxis.
We also recommend Trading Suppliers and Manufacturers of ecallantide (cas 460738-38-9). Pls Click Website Link as below: cas 460738-38-9 suppliers
Prev:Hydrometallurgical extraction of zinc from CaO treated EAF dust in ammonium chloride solution
Next:Analysis of hereditary angioedema attacks requiring a second dose of ecallantide (cas 460738-38-9)) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Critical role of kallikrein in hereditary angioedema pathogenesis: A clinical trial of ecallantide (cas 460738-38-9), a novel kallikrein inhibitor07/18/2019
- ecallantide (cas 460738-38-9) (DX-88) for acute hereditary angioedema attacks: Integrated analysis of 2 double-blind, phase 3 studies07/17/2019
- Outcomes after ecallantide (cas 460738-38-9) treatment of laryngeal hereditary angioedema attacks07/16/2019
- Response time for ecallantide (cas 460738-38-9) treatment of acute hereditary angioedema attacks07/15/2019
- Effectiveness of ecallantide (cas 460738-38-9) in treating angiotensin-converting enzyme inhibitor–induced angioedema in the emergency department07/14/2019
- ecallantide (cas 460738-38-9) for the Acute Treatment of Angiotensin-Converting Enzyme Inhibitor–Induced Angioedema: A Multicenter, Randomized, Controlled Trial07/13/2019
- Analysis of hereditary angioedema attacks requiring a second dose of ecallantide (cas 460738-38-9)07/12/2019
